BPC-157 research overview — structure, published in-vitro signaling, and the analytical documentation US laboratories expect on every batch.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein. It is one of the most heavily researched stable gastric peptides in the USA laboratory literature.
Structure
- Sequence: GEPPPGKPADDAGLV
- 15 amino acids, no disulfide bridges
- Average mass approximately 1419.5 Da
- Notable acid- and enzymatic-stability profile
Published research signaling
Published in-vitro and animal-model literature describes BPC-157 acting on multiple growth-factor and angiogenesis-related pathways, including modulation of VEGFR2 expression and nitric-oxide signaling. These findings are research observations only and do not establish therapeutic outcomes in humans.
What a verified BPC-157 COA shows
- ≥99% HPLC purity
- LC-MS confirmed exact mass
- Counterion (typically acetate) identity and percent
- Bacterial endotoxin per analytical method
Research use only. PeptAra supplies materials strictly for in vitro and laboratory research. Nothing in this article constitutes medical, therapeutic, or dosage advice for human or animal use.
